Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
19 Leser
Artikel bewerten:
(0)

Cardiac Biomarkers Market Growing at 12.75% CAGR to 2018

DALLAS, November 10, 2014 /PRNewswire/ --

ReportsnReports.com adds Global Cardiac Biomarkers Market 2014-2018 research report of 105 pages to its online industry intelligence and business data library. This research forecasts the Global Cardiac Biomarkers market to grow at a CAGR of 12.75% over the period 2013-2018. Complete report is available at http://www.reportsnreports.com/reports/314046-global-cardiac-biomarkers-market-2014-2018.html .

This report covers the present scenario and the growth prospects of the Global Cardiac Biomarkers market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of devices and assays used for cardiac biomarkers to diagnose various cardiovascular diseases. A cardiac biomarker is defined as a measurable substance that is an indicator used in the diagnosis and risk stratification related to cardiovascular disease (CVDs) such as acute coronary syndrome (ACS), coronary syndromes, myocardial infarction (MI), and heart failure. Some of the cardiac biomarkers include creatine kinase (CK) MB, troponins (cTnI and cTnT), BNP, NT-proBNP, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobin, and sCD40L. Cardiac biomarker assays help medical professionals to understand and differentiate between myocardial infarction and angina, which assists in the diagnosis and treatment of CVDs. The abnormal concentration of these biomarkers will act as significant predictors of an adverse cardiovascular condition. Cardiac point of care (POC) testing offers reliable measurement of cardiac biomarkers and provides results within one hour of testing. In addition to saving time, some cardiac POC tests have been modified to improve the accuracy of the measurement of enzymes to reduce operational error.

The cardiac biomarkers market is segmented based on the following types of assays: Troponin (cTnI and cTnT), BNP & NT-proBNP, CK-MB, Myogloblin and Others (hs-CRP, D-Dimer, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobin, AST, FFAu, and sCD40L). The Global Cardiac Biomarkers Market 2014-2018 research report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Cardiac Biomarkers market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Companies discussed in the cardiac biomarkers market report with forecasts to 2018 include Abbott Laboratories, Alere, Ortho Clinical Diagnostics, Roche Diagnostics, AniBiotech, Axis-Shield, Beckman Coulter, Becton, Dickinson and Co., BG Medicine, Biomerieux, Boston Scientific, Critical Diagnostics, diaDexus, LifeSign, Mitsubishi Chemical Europe, Nanomix, Radiometer Medical, Randox Laboratories, Response Biomedical, Siemens Healthcare, Sierra Resources International, Singulex, Thermo Scientific and Trinity Biotech. Order a copy of this research at http://www.reportsnreports.com/Purchase.aspx?name=314046 . This report and its market analysis is supported with 63 exhibits on the industry and its players.

Biomarker Partnering Terms and Agreements is another research of 1048 pages that provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the world's leading healthcare companies. This report contains over 700 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , stage of development, deal type, therapy area, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products. Complete report is available at http://www.reportsnreports.com/reports/56447-biomarker-partnering-terms-and-agreements.html .

The Global Cardiac POC Market 2014-2018 research report forecasts the cardiac POC industry to grow at 14.40% CAGR to 2018. Cardiac POC is a medical test performed near to the site of the patient. The Cardiac POCs are simple medical blood tests that include cholesterol and coagulation testing. Cardiac POC tests include Troponin and brain natriuretic peptide tests, which are used to diagnose cardiovascular conditions such as acute myocardial infarction, coronary syndromes and heart failure. These tests help in the detection of enzymes released during failure of the heart and in critical cardiac conditions such as creating kinase, troponin, lactate dehydrogenase isoenzymes and brain natriuretic peptides. The Cardiac POC tests helps to understand and differentiate better between myocardial infarction and angina, which help to diagnose the patient for a specific disease. These tests or assays offer reliable measurement of the markers, released during heart failure, and provide results within one hour of testing. In addition, to save time, a few Cardiac POC tests have been modified to measure enzymes to reduce operational error and simplify performance. Thus, these tests help significantly in reducing the turnaround time from testing to end results by allowing immediate patient response and effective treatment, or the discharge of patients. To calculate the market size, the report considers revenue generated from the sales of two type of tests: Troponin and brain natriuretic peptide tests, which are used to treat Cardiac POC. Furthermore, the report considers revenue generated from the following type of tests - Biosite Triage, Cobas and i-STAT. The report also presents the vendor landscape and a corresponding detailed analysis of the top three vendors in the Global Cardiac POC market. In addition, it discusses the major drivers that influence the growth of the Global Cardiac POC market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market. Companies like Alere Inc., Abbott Laboratories, Roche Diagnostics, Beckman Coulter, Inc., BG Medicine Inc., Boston Scientific Corp, Medtronic Inc. and Randox Laboratories Ltd. are discussed in this research available at http://www.reportsnreports.com/reports/293691-global-cardiac-poc-market-2014-2018.html .

Explore more reports on the biotechnology market at http://www.reportsnreports.com/market-research/biotechnology/ and the overall healthcare industry at http://www.reportsnreports.com/market-research/healthcare/ .

About Us:

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
sales@reportsandreports.com

Connect With Us on:

Facebook: https: //http://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml


Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.